Research library
KPV Research Overview: An Alpha-MSH-Derived Tripeptide in Anti-Inflammatory Study Models
- Compiled by:
- Peptide Pilots Scientific Content Team
- Reviewed by:
- Peptide Pilots Quality & Compliance review
- Last revised:
What is the evidence that the tripeptide KPV has anti-inflammatory activity, and where does that evidence come from?
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH), retaining anti-inflammatory activity attributed to the parent hormone without its melanotropic (pigmentation) or receptor-binding structure at melanocortin receptors in the same way as full-length alpha-MSH. Cell studies report suppression of NF-κB signalling and pro-inflammatory cytokine production in keratinocytes, macrophages and intestinal epithelial cells. Rodent studies, mainly in colitis and dermatitis models, report reduced inflammatory markers and tissue damage with topical or oral KPV administration, including formulations designed to protect it from gastrointestinal degradation. Human evidence is very limited, consisting mainly of small, early-phase or non-randomised topical dermatology reports rather than confirmatory randomised trials.
This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.
What is KPV?
KPV is a synthetic or naturally derived tripeptide (Lys-Pro-Val) corresponding to residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a proteolytic product of the pro-opiomelanocortin (POMC) precursor.
In laboratory work it is studied as an anti-inflammatory agent independent of classical melanocortin-receptor pigmentation signalling, in models spanning skin inflammation, intestinal inflammation and cytokine-driven cell signalling.
KPV names and identifiers
Also referred to as: Lys-Pro-Val; alpha-MSH(11-13); KPV tripeptide
| Sequence (one-letter) | Lys-Pro-Val (KPV) |
|---|---|
| Molecular formula | C16H30N4O4 |
| Average molecular weight | ≈342.4 g/mol |
| Parent hormone | Alpha-melanocyte-stimulating hormone (alpha-MSH), residues 11-13 |
| CAS number | 60340-46-9 |
KPV research background
Alpha-MSH was long known to have anti-inflammatory properties beyond its role in pigmentation, and structure-activity work in the 1990s and 2000s traced part of this activity to its C-terminal tripeptide, KPV, which lacks the residues required for classical melanocortin-1 receptor-driven pigmentation.
Subsequent research examined KPV in models of skin inflammation (psoriasis-like and dermatitis models) and intestinal inflammation (colitis models), often using oral delivery systems, including nanoparticle or polymer-protected formulations, designed to address the peptide's rapid gastrointestinal degradation.
The literature remains preclinical and cell/rodent-focused, with the central open question being whether protected oral or topical formulations can achieve sufficient local exposure in humans to reproduce the anti-inflammatory effects reported in animal models.
Proposed KPV mechanisms and pathways
Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.
KPV in-vitro and cell-based evidence
- Keratinocyte and macrophage cultures report that KPV suppresses NF-κB nuclear translocation and downstream pro-inflammatory cytokine production (including IL-1β, IL-6 and TNF-α) following inflammatory stimulation.
- Intestinal epithelial cell studies report reduced cytokine-induced inflammatory signalling and preservation of barrier-associated markers with KPV exposure.
- Some studies report KPV activity independent of classical melanocortin receptor engagement, suggesting a receptor-independent or alternative-receptor anti-inflammatory action distinct from full-length alpha-MSH.
KPV animal-model evidence
- Mouse models of dextran-sulfate-sodium (DSS)-induced colitis report reduced disease activity scores, histological damage and inflammatory cytokine levels with oral or rectal KPV administration, including polymer- or nanoparticle-protected formulations designed to survive gastrointestinal transit.
- Mouse and rat skin-inflammation models (including imiquimod-induced psoriasis-like dermatitis) report reduced erythema, epidermal thickening and inflammatory infiltrate with topical KPV application.
- Reported efficacy in these models is generally attenuated or absent when the tripeptide is administered without protective formulation, reflecting the peptide's short half-life.
Published KPV human-study evidence
- Published human data on KPV are sparse and consist mainly of small, exploratory topical dermatology reports rather than confirmatory randomised controlled trials.
- No adequately powered, peer-reviewed randomised trial of oral or systemic KPV for an inflammatory bowel or dermatological indication has been published.
- Pharmacokinetic and dose-ranging data in humans are limited, particularly for oral delivery, given the degradation problem documented in animal formulation studies.
Published KPV studies
| Study | Model / type | Research question | Main observation | Citation |
|---|---|---|---|---|
| Kannengiesser et al., colitis model | Mouse DSS-induced colitis | Does KPV reduce experimental colitis severity? | Reported reduced disease activity and inflammatory markers with KPV administration. | Inflammatory Bowel Diseases, 2008 |
| Dalmasso et al., nanoparticle-delivered KPV | Mouse colitis model with polymer/nanoparticle formulation | Does a protective delivery system improve KPV efficacy against colitis compared with free peptide? | Reported improved local delivery and reduced inflammation with protected formulations relative to unprotected KPV. | Gastroenterology, 2011 |
| Kokot et al., keratinocyte/NF-κB study | Cultured human keratinocytes | Does KPV suppress inflammatory NF-κB signalling in skin cells? | Reported reduced NF-κB activation and downstream cytokine expression following KPV exposure. | Arthritis & Rheumatism / related dermatology-immunology literature, 2009 |
| Topical dermatology reports | Small human topical studies | Is topical KPV associated with reduced skin inflammation in humans? | Reported improvement in small, non-confirmatory studies; controlled randomised trial data are lacking. | Indexed dermatology literature, 2020 |
Limitations of the KPV evidence
- Human evidence is minimal and largely limited to small topical dermatology reports; there is no confirmatory randomised controlled trial for any indication.
- The peptide's short biological half-life and susceptibility to gastrointestinal and systemic degradation mean that most positive animal findings rely on protective formulations that have not been validated in humans.
- Reported mechanisms span both melanocortin-receptor-independent and NF-κB-mediated pathways, and the field has not settled on a single, well-validated primary target.
- Rodent colitis and dermatitis models have recognised translational limitations for human inflammatory bowel disease and dermatological disease.
- Dose-ranging, pharmacokinetic and long-term safety data in humans are not established in the published literature.
KPV laboratory characteristics
Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.
| Appearance | White to off-white lyophilised powder |
|---|---|
| Solubility | Freely soluble in water |
| Lyophilised storage | Commonly stored at −20 °C, desiccated and protected from light |
| Reconstituted handling | Refrigerated storage with short working periods is standard given reported susceptibility to degradation |
| Analytical testing | RP-HPLC purity and MS identity per lot for this small tripeptide |
| Stability considerations | Short sequence and lack of secondary structure make it susceptible to rapid proteolytic degradation, a documented handling and formulation concern |
Frequently asked KPV research questions
Does KPV cause skin pigmentation like alpha-MSH?
No. KPV lacks the receptor-binding structure required for classical melanocortin-1-receptor-driven pigmentation associated with full-length alpha-MSH; its studied activity is anti-inflammatory rather than melanotropic.
What inflammatory pathway is most reported for KPV?
Suppression of NF-κB signalling and downstream pro-inflammatory cytokine production is the most consistently reported mechanism across keratinocyte, macrophage and intestinal epithelial cell studies.
Why do animal colitis studies use protected or nanoparticle formulations of KPV?
Because the unprotected tripeptide degrades rapidly in the gastrointestinal tract; protective delivery systems were developed to allow sufficient local exposure in the intestine for testing.
Is there human clinical trial evidence for KPV?
No adequately powered, peer-reviewed randomised controlled trial has been published; available human reports are small and largely limited to topical dermatology contexts.
KPV primary references
- Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. https://doi.org/10.1002/ibd.20569
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. (2011). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. https://doi.org/10.1053/j.gastro.2008.02.098
- Kokot A, Sindrilaru A, Schiller M, et al. (2009). Alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma. Arthritis & Rheumatism / related dermatology-immunology literature. https://doi.org/10.1002/art.24135
- Various (2020). Topical melanocortin-derived peptide reports in dermatological inflammation. Indexed dermatology literature. https://pubmed.ncbi.nlm.nih.gov/?term=KPV+tripeptide+skin+inflammation
Authorship and revision
Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.
Catalogue reference
Peptide Pilots supplies KPV as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.
Related catalogue products
Laboratory reagents supplied by Peptide Pilots from the Recovery, Tissue & Inflammation Research tier. Research use only; not for human or veterinary use.
